US Bancorp DE Has $54,000 Stock Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

US Bancorp DE reduced its position in OrthoPediatrics Corp. (NASDAQ:KIDS) by 15.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 2,309 shares of the company’s stock after selling 412 shares during the period. US Bancorp DE’s holdings in OrthoPediatrics were worth $54,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Quarry LP acquired a new stake in OrthoPediatrics in the 3rd quarter valued at about $25,000. Rhumbline Advisers lifted its stake in OrthoPediatrics by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,411 shares of the company’s stock valued at $612,000 after purchasing an additional 1,042 shares during the last quarter. Quantbot Technologies LP lifted its stake in OrthoPediatrics by 42.2% in the 3rd quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock valued at $157,000 after purchasing an additional 1,712 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in OrthoPediatrics by 125.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock valued at $94,000 after purchasing an additional 1,929 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in OrthoPediatrics in the 4th quarter valued at about $48,000. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at OrthoPediatrics

In other news, CEO David R. Bailey sold 6,620 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the transaction, the chief executive officer now directly owns 319,155 shares of the company’s stock, valued at approximately $7,934,193.30. This trade represents a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the transaction, the general counsel now directly owns 110,767 shares in the company, valued at $2,753,667.62. This represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,732 shares of company stock valued at $589,978. 31.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $42.00 price target on shares of OrthoPediatrics in a report on Wednesday, March 5th. Stifel Nicolaus lowered their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Finally, Truist Financial lowered their price target on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th.

OrthoPediatrics Stock Up 1.8 %

OrthoPediatrics stock opened at $25.42 on Wednesday. The stock has a market cap of $617.38 million, a P/E ratio of -20.67 and a beta of 1.22. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. OrthoPediatrics Corp. has a twelve month low of $21.02 and a twelve month high of $35.99. The company’s 50-day moving average price is $24.79 and its two-hundred day moving average price is $25.53.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The company had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. During the same period last year, the firm earned ($0.23) earnings per share. As a group, analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.